# EDGAR Filing Document

**Accession Number:** 0001630864
**File Stem:** 0001630864-26-000008
**Filing Date:** 2026-3
**Character Count:** 8810
**Document Hash:** eb64ad59f7a29aceb3e0485edf265fec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001630864-26-000008.hdr.sgml**: 20260324

**ACCESSION NUMBER**: 0001630864-26-000008

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260323

**FILED AS OF DATE**: 20260324

**DATE AS OF CHANGE**: 20260324

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Duker Jay S.
- **CENTRAL INDEX KEY:** 0001630864

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-51122
- **FILM NUMBER:** 26786199

**MAIL ADDRESS:**
- **STREET 1:** C/O EYEPOINT
- **STREET 2:** 480 PLEASANT ST
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EyePoint, Inc.
- **CENTRAL INDEX KEY:** 0001314102
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 262774444
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 480 PLEASANT STREET
- **STREET 2:** SUITE C400
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 617-926-5000

**MAIL ADDRESS:**
- **STREET 1:** 480 PLEASANT STREET
- **STREET 2:** SUITE C400
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EyePoint Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20180330

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** pSivida Corp.
- **DATE OF NAME CHANGE:** 20080619

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** pSivida LTD
- **DATE OF NAME CHANGE:** 20050111

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Duker Jay S.<br><sub>(Last) (First) (Middle)</sub><br>C/O EYEPOINT, INC.<br>480 PLEASANT STREET, SUITE C400<br><sub>(Street)</sub><br>WATERTOWN, MA 02472<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-23 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President and CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>EyePoint, Inc. [ EYPT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-03-23 |  | J<sup>(1)</sup> |  | 76766.00 | D | 13.11<sup>(1)</sup> | 986.00 | D |  |
| Common Stock | 2026-03-23 |  | J<sup>(1)</sup> |  | 76766.00 | A | 13.11<sup>(1)</sup> | 177431.00 | I | By Family Trust<sup>(2)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $13.13 | 2026-03-23 |  | J<sup>(1)</sup> |  |  | 52500.00 | <sup>(3)</sup> | 2031-02-09 | Common Stock | 52500.00 | 8.75<sup>(1)</sup> | 7800.00 | D |  |
| Stock Option (Right to Buy) | $13.13 | 2026-03-23 |  | J<sup>(1)</sup> |  | 52500.00 |  | <sup>(3)</sup> | 2031-02-09 | Common Stock | 52500.00 | 8.75<sup>(1)</sup> | 52500.00 | I | By Family Trust<sup>(2)</sup> |
| Stock Option (Right to Buy) | $20.40 | 2026-03-23 |  | J<sup>(1)</sup> |  |  | 97500.00 | <sup>(4)</sup> | 2034-01-04 | Common Stock | 97500.00 | 9.57<sup>(1)</sup> | 82500.00 | D |  |
| Stock Option (Right to Buy) | $20.40 | 2026-03-23 |  | J<sup>(1)</sup> |  | 97500.00 |  | <sup>(4)</sup> | 2034-01-04 | Common Stock | 97500.00 | 9.57<sup>(1)</sup> | 97500.00 | I | By Family Trust<sup>(2)</sup> |

---

### Footnotes:

(1) On March 23, 2026, the reporting person sold owned shares of ("Shares") and options to purchase ("Options") Common Stock of EyePoint, Inc. (the "Company") to the Duker Family 2024 Irrevocable Trust, (the "Family Trust"), in exchange for a promissory note in the principal amount of $2,398,220.93, representing the fair market value of the Shares and Options. For Shares, the fair market value was determined by utilizing the average of the high and low per share trading price on the date of the sale. For Options, the fair market value was determined using a Black Scholes model. The securities held in the Family Trust are for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the Family Trust. The reporting person disclaims beneficial ownership of the security and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

(2) These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

(3) At the time of the sale, the portion of the options sold to the Family Trust and the remaining portion of the option retained by the reporting person was vested in full.

(4) The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the sale, the portion of the option that was sold to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 5, 2028.

**Signature:** /s/  Ron Honig, Attorney-in-Fact  
**Date:** 2026-03-24

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**